<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Jazz Pharmaceuticals Plc — News on 6ix</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc</link>
<description>Latest news and press releases for Jazz Pharmaceuticals Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 20:15:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/jazz-pharmaceuticals-plc" rel="self" type="application/rss+xml" />
<item>
<title>Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-to-report-first-quarter-financial-results-on-may-5-2026</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-to-report-first-quarter-financial-results-on-may-5-2026</guid>
<pubDate>Tue, 21 Apr 2026 20:15:00 GMT</pubDate>
<description>Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 first quarter financial results on Tuesday, May 5, 2026, after the close of the U.S. financial markets. Company management will host a webcast at 4:30 p.m. ET to discuss the results and provide a business and financial update.</description>
</item>
<item>
<title>Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin)</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-to-present-data-at-asco-2026-highlighting-advancements-for-ziiherar-zanidatamab-hrii-in-gastroesophageal-adenocarcinoma-and-zepzelcar-lurbinectedin</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-to-present-data-at-asco-2026-highlighting-advancements-for-ziiherar-zanidatamab-hrii-in-gastroesophageal-adenocarcinoma-and-zepzelcar-lurbinectedin</guid>
<pubDate>Tue, 21 Apr 2026 20:05:00 GMT</pubDate>
<description>Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present three rapid oral and seven poster presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 29-June 2, 2026, in Chicago. The data reflect Jazz's continued momentum in oncology and the Company's focus on advancing treatment approaches in difficult-to-treat cancers through late-stage clinical research, real-world evidence and ongoing pipeline innovati</description>
</item>
<item>
<title>Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-to-present-research-on-epidiolexr-cannabidiol-and-xywavr-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-at-the-2026-american-academy-of-neurology-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-to-present-research-on-epidiolexr-cannabidiol-and-xywavr-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-at-the-2026-american-academy-of-neurology-annual-meeting</guid>
<pubDate>Thu, 09 Apr 2026 11:45:00 GMT</pubDate>
<description>Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will present six abstracts, including one oral presentation, at the 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026, in Chicago.</description>
</item>
<item>
<title>Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-to-participate-in-needham-virtual-healthcare-conference-3</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-to-participate-in-needham-virtual-healthcare-conference-3</guid>
<pubDate>Wed, 01 Apr 2026 20:15:00 GMT</pubDate>
<description>Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 25th Annual Needham Healthcare Conference. Company management will participate in a fireside chat on Wednesday, April 15, 2026, at 8:45 a.m. PT / 11:45 a.m. ET / 4:45 p.m. IST.</description>
</item>
<item>
<title>American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/american-nutrition-association-announces-initiative-with-jazz-pharmaceuticals-to-advance-evidence-based-sodium-reduction-and-cardiovascular-health-education</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/american-nutrition-association-announces-initiative-with-jazz-pharmaceuticals-to-advance-evidence-based-sodium-reduction-and-cardiovascular-health-education</guid>
<pubDate>Tue, 24 Mar 2026 17:49:00 GMT</pubDate>
<description>The American Nutrition Association (ANA) today announced its initiative with Jazz Pharmaceuticals to provide evidence-based nutritional education to support people living with narcolepsy or idiopathic hypersomnia (IH) sleep disorders associated with elevated cardiovascular (CV) and cardiometabolic (CM) risk, which make targeted, proactive nutrition even more critical. Together, they aim to translate the latest nutrition science into actionable, patient-centered guidance for people living with th</description>
</item>
<item>
<title>Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-to-present-compelling-clinical-and-pre-clinical-data-advancing-oncology-research-at-aacr-2026</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-to-present-compelling-clinical-and-pre-clinical-data-advancing-oncology-research-at-aacr-2026</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>Seven presentations deliver new insights into zanidatamab's differentiated HER2 biology, emerging pre-clinical data on dordaviprone and related imipridones,</description>
</item>
<item>
<title>Rylaze (Jazz Pharmaceuticals) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/rylaze-jazz-pharmaceuticals-market-research-report-2026-epidemiology-pipeline-analysis-trends-strategies-and-forecasts-2020-2025-2025-2030f-2035f</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/rylaze-jazz-pharmaceuticals-market-research-report-2026-epidemiology-pipeline-analysis-trends-strategies-and-forecasts-2020-2025-2025-2030f-2035f</guid>
<pubDate>Fri, 13 Mar 2026 11:08:00 GMT</pubDate>
<description>Opportunities in the Rylaze market include growth from investments in pediatric oncology drugs, demand for personalized and safer leukemia therapies, and the expansion of cancer centers. Advancements in recombinant formulations and flexible dosing enhance treatment adherence, while rising investment in novel biologics further drives market growth.Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Rylaze Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added</description>
</item>
<item>
<title>Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-announces-full-year-and-fourth-quarter-2025-financial-results-and-provides-2026-financial-guidance</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-announces-full-year-and-fourth-quarter-2025-financial-results-and-provides-2026-financial-guidance</guid>
<pubDate>Tue, 24 Feb 2026 21:05:00 GMT</pubDate>
<description>Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2025 and provided financial guidance for 2026.</description>
</item>
<item>
<title>Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-participate-upcoming-investor-211500132</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-participate-upcoming-investor-211500132</guid>
<pubDate>Tue, 17 Feb 2026 21:15:00 GMT</pubDate>
<description>Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following investor conferences:</description>
</item>
<item>
<title>Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-report-fourth-quarter-211500096</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-report-fourth-quarter-211500096</guid>
<pubDate>Tue, 10 Feb 2026 21:15:00 GMT</pubDate>
<description>Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced its fourth quarter and full year 2025 financial results will be reported on February 24, 2026, after the close of the U.S. financial markets. Company management will host a webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss the results and provide a business and financial update.</description>
</item>
<item>
<title>Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-appoints-thomas-riga-chief-business-officer-2026-01-08</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-appoints-thomas-riga-chief-business-officer-2026-01-08</guid>
<pubDate>Thu, 08 Jan 2026 05:00:00 GMT</pubDate>
<description>Mr. Riga brings over 25 years of commercial and operational experience with proven success leading transformative corporate development strategies and</description>
</item>
<item>
<title>Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/ziiherar-zanidatamab-hrii-combinations-achieve-unprecedented-results-first-line-1</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/ziiherar-zanidatamab-hrii-combinations-achieve-unprecedented-results-first-line-1</guid>
<pubDate>Tue, 06 Jan 2026 05:00:00 GMT</pubDate>
<description>Positive Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line metastatic GEA and Ziihera plus chemotherapy</description>
</item>
<item>
<title>Jazz Pharmaceuticals to Participate in Upcoming Investor Events</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-participate-upcoming-investor-events-2025-12-17</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-participate-upcoming-investor-events-2025-12-17</guid>
<pubDate>Wed, 17 Dec 2025 05:00:00 GMT</pubDate>
<description>DUBLIN, Dec. 17, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following investor</description>
</item>
<item>
<title>Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-present-extensive-new-data-and-real-world-evidence-highlighting</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-present-extensive-new-data-and-real-world-evidence-highlighting</guid>
<pubDate>Fri, 05 Dec 2025 05:00:00 GMT</pubDate>
<description>New interim results from the EpiCom trial, a prospective evaluation of behavioral outcomes in patients with tuberous sclerosis complex, suggest improvements</description>
</item>
<item>
<title>Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-present-pivotal-phase-3-results-ziiherar-zanidatamab-hrii</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-present-pivotal-phase-3-results-ziiherar-zanidatamab-hrii</guid>
<pubDate>Tue, 02 Dec 2025 05:00:00 GMT</pubDate>
<description>Late-breaking HERIZON-GEA-01 presentation highlights the expanding clinical profile of Ziihera across HER2-driven gastrointestinal cancersJazz to host</description>
</item>
<item>
<title>Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-participate-citis-2025-global-healthcare-conference-2025-11-18</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-participate-citis-2025-global-healthcare-conference-2025-11-18</guid>
<pubDate>Tue, 18 Nov 2025 05:00:00 GMT</pubDate>
<description>DUBLIN, Nov. 18, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in Citi's 2025 Global</description>
</item>
<item>
<title>Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/positive-herizon-gea-01-phase-3-results-support-ziiherar-zanidatamab-hrii-as-her2-targeted-agent-of-choice-and-ziihera-combination-regimens-as-new-standard-of-care-in-first-line-her2-positive-locally-advanced-or-metastatic-gastroesophageal-adenocarcinoma</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/positive-herizon-gea-01-phase-3-results-support-ziiherar-zanidatamab-hrii-as-her2-targeted-agent-of-choice-and-ziihera-combination-regimens-as-new-standard-of-care-in-first-line-her2-positive-locally-advanced-or-metastatic-gastroesophageal-adenocarcinoma</guid>
<pubDate>Mon, 17 Nov 2025 11:00:00 GMT</pubDate>
<description>Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera® (zanidatamab-hrii) in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra® (tislelizumab), as first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including cancers of the stomach, gastroesophageal junction and esophagus.</description>
</item>
<item>
<title>Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarc...</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/positive-herizon-gea-01-phase-3-results-support-ziiherar-zanidatamab-hrii-her2</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/positive-herizon-gea-01-phase-3-results-support-ziiherar-zanidatamab-hrii-her2</guid>
<pubDate>Mon, 17 Nov 2025 05:00:00 GMT</pubDate>
<description>Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard</description>
</item>
<item>
<title>Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-showcases-new-clinical-and-translational-data-modeysotm</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-showcases-new-clinical-and-translational-data-modeysotm</guid>
<pubDate>Tue, 11 Nov 2025 05:00:00 GMT</pubDate>
<description>Data highlight continued progress in Jazz's brain tumor research and demonstrate the company's commitment to advancing treatment options for patients with</description>
</item>
<item>
<title>Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-announces-third-quarter-2025-financial-results-and-updates-2025</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-announces-third-quarter-2025-financial-results-and-updates-2025</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>– Modeyso™ approved as the first and only treatment for recurrent H3 K27M-mutant DMG – – Zepzelca® and atezolizumab (Tecentriq®) combination approved as</description>
</item>
</channel>
</rss>